Skip to main content
TipRanks
Go Ultimate75% OFF

Tanvex Biopharma (TANVF) AI Stock Analysis

6 Followers
TANVF

Tanvex Biopharma

(Other OTC:TANVF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Revenue GrowthThe sharp 2025 revenue increase indicates meaningful commercial expansion and improving market traction. If the growth is sustained, it can provide greater operating scale, support investment in development and market access, and strengthen the company’s ability to build a broader biologics business.
Negative Factors
Persistent Operating LossesPersistent operating and net losses show that the business has not yet reached earnings stability despite strong revenue growth. Continued losses can constrain reinvestment, weaken shareholder returns, and make future performance dependent on achieving much better operating leverage and cost control.

Tanvex Biopharma Business Overview & Revenue Model

Company Description

Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medici...

Tanvex Biopharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TANVF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4169TW:416954NeutralTWD 8.00B-303.75―0.26%――
TW:4147TW:414747NeutralTWD 17.57B-108.83――7.02%25.72%
TW:6547TW:654740UnderperformTWD 15.41B-410.81――44.37%78.11%

* General Sector Average

Performance Comparison

0%100%200%300%TW:4147TW:4169TW:6547TW:6586TW:6589Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TANVF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4147TaiMed Biologics Inc.64.30-1.90-2.87%
TW:4169TCM Biotech International Corp.121.50-58.77-32.60%
TW:6547Medigen Vaccine Biologics Corp.46.8511.6533.10%
TW:6586CHO Pharma, Inc.76.3046.70157.77%
TW:6589EirGenix, Inc.55.60-19.00-25.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.